| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 33.653 | 41.951 | 43.740 | 46.258 | 76.260 | 95.086 | 103.402 | 120.289 | 133.458 |
| Total Income - EUR | - | 33.653 | 41.951 | 43.740 | 46.258 | 76.260 | 95.087 | 103.403 | 120.290 | 133.459 |
| Total Expenses - EUR | - | 157 | 85 | 370 | 878 | 28.374 | 31.631 | 37.342 | 41.539 | 45.644 |
| Gross Profit/Loss - EUR | - | 33.495 | 41.866 | 43.370 | 45.380 | 47.887 | 63.456 | 66.061 | 78.751 | 87.815 |
| Net Profit/Loss - EUR | - | 32.486 | 40.607 | 42.057 | 43.992 | 47.124 | 62.505 | 65.027 | 77.548 | 83.811 |
| Employees | - | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 |
Check the financial reports for the company - Endocrine. Ro Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | 32.765 | 40.958 | 42.351 | 44.431 | 49.783 | 65.247 | 70.410 | 81.309 | 88.968 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | 0 | 0 | 519 | 25.052 | 34.443 | 28.938 | 49.499 | 78.363 | 69.335 |
| Cash | - | 32.765 | 40.958 | 41.832 | 19.379 | 15.340 | 36.309 | 20.911 | 2.946 | 19.633 |
| Shareholders Funds | - | 32.530 | 40.660 | 42.109 | 44.043 | 47.174 | 62.554 | 65.076 | 77.596 | 83.859 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 235 | 298 | 243 | 389 | 2.609 | 2.693 | 5.334 | 3.713 | 5.108 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Endocrine. Ro Srl